

CURRICULUM VITAE

Date Prepared: September 23, 2009

Name: Haiden Ashby Huskamp

Office Address: Department of Health Care Policy
180 Longwood Avenue
Boston, MA 02115

Work Phone: 617-432-0838

Work E-Mail: huskamp@hcp.med.harvard.edu

Work FAX: 617-432-0173

Education

1989	B.A. (Honors)	Public Policy	Duke University
1997	Ph.D.	Health Policy, Economics Concentration; Advisor: Richard G. Frank, Ph.D.	Harvard University

Faculty Academic Appointments

1997-2004	Assistant Professor of Health Care Policy	Health Care Policy	Harvard Medical School
2004-	Associate Professor of Health Care Policy	Health Care Policy	Harvard Medical School

Other Professional Positions

1988-1989	Research Assistant	National Governors' Association	Washington, DC
1989-1990	Program Analyst	U.S. Department of Health and Human Services	Washington, DC
1990-1992	Associate	Alpha Center for Health Policy	Washington, DC

Committee Service

1994-1999	Board of Freshman Advisors Member	Harvard College
1998-1999	Junior Faculty Search Committees Member	Harvard Medical School
1999-2001	Committee for Undergraduate Education in Health Policy Member	Harvard University
2000-2001	Harvard Health Caucus Advisory Board Member	Harvard Medical School
2000-	Harvard University Standing Committee on the Degree of	Harvard University

	Doctor of Health Policy Member	
2005-	Harvard Medical School Medical Education Reform Committee on Fundamentals of Medicine Member	Harvard Medical School
	Subcommittee on Health Policy and Managerial Sciences Co-chair	
2006-	Harvard Medical School Center for Population Health Medical Education Subcommittee on Pre-Clinical Education Co-chair	Harvard Medical School
2007-2008	Harvard Medical School Strategic Advisory Group on Education Member	Harvard Medical School
2009-	Harvard Medical School Curriculum Committee Member	Harvard Medical School

Professional Societies

1990-	AcademyHealth Member
1999-	International Health Economics Association Member
2006-	American Society of Health Economists Member

Grant Review Activities

1998	Ad-hoc Grant Reviewer, The Substance Abuse and Mental Health Services Administration	U.S. Department of Health and Human Services
2002-	Ad-hoc Grant Reviewer, Changes in health Care Financing and Organization (HCFO) Program	Robert Wood Johnson Foundation
2005-	Ad-hoc Reviewer, Study Section Review Panels	National Institute of Mental Health
2006	Ad-hoc Reviewer, Health Services Organization and Delivery Study Section	National Institute of Health

Editorial Activities

1997-	Ad-hoc Reviewer	Journal of Health Economics Inquiry
1998-	Ad-hoc Reviewer	Health Affairs
1999-	Ad-hoc Reviewer	Health Care Financing Review
2000-	Ad-hoc Reviewer	Administration and Policy in Mental Health
2001-	Ad-hoc Reviewer	Psychiatric Services Milbank Quarterly

2002-	Ad-hoc Reviewer	Journal of Mental Health Policy and Economics Journal of Economics and Management Strategy Medical Care Health Services Research
2003-	Ad-hoc Reviewer	Journal of General Internal Medicine
2004-	Ad-hoc Reviewer	New England Journal of Medicine Journal of Health Politics, Policy and Law Archives of General Psychiatry
2006-	Ad-hoc Reviewer	PharmacoEconomics American Journal of Managed Care
2004-	Co-Editor	Psychiatric Services, Grand Rounds Column
2008-	Editorial Board Member	Medical Care Research and Review

Honors and Prizes

1992-1994	Trainee	Agency for Health Care Policy and Research
1994-1995	Trainee	National Institute of Mental Health
1996-1997	Fellow	Alfred P. Sloan Foundation
1998-1999	Fellow	Prudential Health Services
2002-2007	Career Development Award	National Institute for Mental Health
2007-2010	Investigator Award in Health Policy Research	Robert Wood Johnson Foundation

Report of Funded and Unfunded Projects

Funded Projects:

Past

1995-2000	Co-Investigator	Brandeis University / National Institute on Drug Abuse Grant #U1 P50 DA10233	\$804,153
-----------	-----------------	---	-----------

Brandeis/Harvard Center for the Study of Managed Care and Drug Abuse Treatment Richard Frank
This project examines the choice of organization and contract structure of managed behavioral health care and estimates the response to contract features for a set of public and private insurance contracts.

1998-1999	PI	Center for Health Care Strategies, Inc./The Robert Wood Johnson Foundation Grant #ML 375	\$87,262
-----------	----	---	----------

Procurement Strategies for Medicaid Managed Care Programs Serving Individuals with Chronic and Disabling
This study examines state and country strategies for the procurement of Medicaid managed care contracts to

serve individuals with chronic and disabling conditions.

1998-1999	Research Fellow	Prudential Health Services Research Fellowship	\$107,531
-----------	-----------------	--	-----------

The Effects of Managed Mental Health Care

Barbara McNeil

This project fosters collaboration between Prudential and Harvard and provides an opportunity for postdoctoral fellows and junior faculty to gain experience in health services research, and particularly in issues pertaining to managed care.

1999-2001	Co-Investigator	Eli Lilly Foundation	\$99,855
-----------	-----------------	----------------------	----------

Managed Care and Therapeutic Choice

Richard Frank

This project examines the impact of benefit design (patient incentives), vendor contract provisions (managed care organization incentives), and provider payment, organization and contract features (provider incentives) on treatment choice for depression, anxiety disorder, and alcohol abuse.

1999-2006	Co-Investigator	Alfred P. Sloan Foundation Grant #98-12-7	\$1,218,054
-----------	-----------------	--	-------------

Managed Care Industry Center

Joseph Newhouse

This grant funds the core of the Harvard Managed Care Industry Center. The purpose of the center is to train new researchers on the industry and to initiate collaborative studies to improve industry performance and to identify best practices. The Center's research focus is on the effects of risk-sharing on quality and outcomes of care for both managed care and managed behavioral health care.

2000-2002	PI	Robert Wood Johnson Foundation Grant #036415	\$70,623
-----------	----	---	----------

The Impact of Medicare Financing Methods on End-of-Life Care

This study examines how different actors involved with providing end-of-life services perceive the strengths and limitations of the current Medicare financing system. In addition, the project explores the implications for future Medicare policy of the issues raised and ways in which the Medicare financing system might be changed to address any problems identified.

2000-2004	Co-Investigator	Northrop Grumman Corp. / DHHS Grant #S-26027	\$927,946
-----------	-----------------	---	-----------

Evaluation of Parity in the Federal Employees Health Benefits Program

Richard Frank

For this study evaluating the effects of requiring parity in coverage of mental health and general medical care services within the Federal Employees Health Benefits Program, the Harvard research team will have lead responsibility for constructing all analysis files based on administrative data for all analyses related to costs, utilization, access and quality. The Harvard team will also have responsibility for analysis of costs and utilization data in both the administrative data sets and for the survey research data. Harvard investigators will also participate in the survey design and analysis of patient satisfaction data. Members of the Harvard team will also work on health plan reviews, focus groups and site visits at OPM and eight health plans. Harvard investigators will be involved in the overall evaluation design, the writing of reports of findings and progress of the research. Harvard will also have responsibility for providing the government with analysis files and detailed documentation.

2000-2005	Co-Investigator	Robert Wood Johnson Foundation Grant #039960	\$389,763
-----------	-----------------	---	-----------

Organization and Financing of Primary Care Depression	Richard Frank
---	---------------

The goal of this activity is to develop a set of economic incentives and organizational arrangements that support recent advances in the understanding of how depression is most effectively treated in a primary care context. Pursuing this overall goal requires engaging in a number of specific activities aimed at developing and specifying the economic model. There are five main activities: 1) Conduct a review of the literature on treating depression in primary care to identify what has been learned about how the economic and organizational context promote or hinder the effective treatment of depression. 2) Examine secondary data sets to identify common treatment patterns for depression in primary care. 3) Identify and familiarize ourselves with innovative treatment programs aimed at depression in the primary care setting. 4) Analyze the incentives and the organizational structures that promote adherence to appropriate clinical choices. 5) Specify a set of economic and organizational principles to be used in developing a demonstration program.

2001-2004	Co-Investigator	Robert Wood Johnson Foundation Grant #42094	\$589,432
-----------	-----------------	--	-----------

Impact of Incentive Formularies on Prescription Drug and Health Care Costs and Utilization	Richard Frank
--	---------------

The fundamental question of how to balance costs, choice of drugs and innovations in the prescription drug area has become one of the more pressing challenges facing the management of health plans. We will trace the diffusion formulary arrangements and analyze factors that influence an employer's or managed care organization's (MCO) decision to use three-tiered formularies and other patient incentive arrangements. Descriptive and multivariate analysis will be used to study the importance of various factors on employer/health plan choices. This study will provide important information for both public and private policymakers on the impacts of one of the new private sector methods of managing pharmaceutical benefits on prescription drug use, pharmacy and total health care spending, and patterns of care.

2000-2005	Co-Investigator	Agency for Healthcare Research and Quality	\$2,740,501
-----------	-----------------	--	-------------

Grant #5 P01 HS10803

Structuring Markets and Competition in Health Care

Joseph Newhouse

This Program Project will develop and apply an overarching conceptual framework, drawn from economic theory, for understanding the roles of purchasers, plans, providers, and patients in a market environment characterized by which payers contract with health plans and plans by capitation. Managed care greatly expands the dimensions upon the market structure itself, which determines how payers, plans, and providers both contract and compete with each other. Alternative market structures have different effects on costs and clinical endpoints. Our Program Project will improve understanding of these effects. The R01 led by Dr. Huskamp examines two types of benefit carve-out arrangements (pharmacy carve-outs and mental health and substance abuse (MHSA) carve-outs) and explores their impacts, including any cost shifting that resulted from use of carve-outs.

2004	PI	Henry J. Kaiser Family Foundation Grant #02-1237-600	\$11,233
------	----	---	----------

Analysis of the New Medicare Prescription Drug Law

This project analyzes the key features of the Medicare Modernization Act of 2003 and discusses implications of these features for cost, access, and quality of care for Medicare beneficiaries.

2004-2006	PI	Technical Assistance Collaborative / MacArthur Foundation Grant #03-78360-000-HCD	\$105,999
-----------	----	---	-----------

Variations in Quality of Depression Treatment among Specialty Mental Health Providers

This study uses claims data from a large managed behavioral health care organization to examine the provision of quality care within a network of specialty mental health providers.

2005-2007	Co-Investigator	Robert Wood Johnson Foundation Grant #056107	\$79,258
-----------	-----------------	---	----------

Uptake and Impact of Health Risk Appraisals

Meredith Rosenthal

Efforts to inform and motivate consumers to make better health and health care choices have diffused throughout the health care market. One of the central components of these consumer health management programs is the health risk appraisal (HRA). HRAs are structured surveys designed to identify a wide range of health risks, including genetic predispositions to disease, poor health habits, and lack of adherence to recommended care for a chronic condition. In this study, we explore the potential of HRAs to engage consumers in health improvement. In particular, we will examine the overall rates of HRA completion in a

privately-insured population, the impact of a consumer financial incentive on HRA completion, the characteristics of consumers who opt to complete an HRA, and early effects of HRAs on utilization and health behavior.

2002-2008	PI	National Institute of Mental Health Grant #K01 MH66109	\$652,337
-----------	----	---	-----------

Economics of Formulary Design and Mental Health Policy

This Mentored Research Scientist Development Award would allow Dr. Haiden Huskamp, a health economist with expertise in mental health policy and economic institutions, to supplement her economic tools with the knowledge and skills needed to conduct clinically-relevant and policy-significant research on the economics of prescription drugs used in the treatment of mental illnesses. The specific aims of this career development proposal are to: 1) develop a greater understanding of clinical decision making related to the use of psychotropic drugs; 2) acquire basic knowledge of psychopharmacology; and 3) expand knowledge of the important economic institutions influencing the prescription drug market. In this undertaking, Dr. Huskamp will be guided by her sponsor, Richard Frank, PhD, and co-sponsors, Andrew Nierenberg, MD, and Ernst Berndt, PhD.

Current

2007-2010	PI	Robert Wood Johnson Foundation Investigator Award in Health Policy Research Program Grant #60468	\$252,902
-----------	----	--	-----------

Has the Revolution Come and Gone? The Societal Value of New Psychotropic Drugs

The past two decades were a period of rapid development of new drug treatments for mental illness. Some believe these new drugs have brought about “revolutionary” changes in the treatment of mental illness. At the same time, the growth in psychotropic drug costs has been explosive. Rapid cost increases combined with high accounting profits have brought increased scrutiny to drug manufacturers over whether the drugs they produce are worth the costs. This project will compare the social costs and benefits of newer psychotropic drugs to assess their social value and then identify ways that the value of psychotropic drug spending can be increased.

2005-2008	Co-Investigator	National Institute of Mental Health Grant #R01 MH061434	\$918,691
-----------	-----------------	--	-----------

Modeling Treatment Use & Effectiveness in Mental Health	Sharon-Lise Normand
---	---------------------

This application seeks continued support for a team of statisticians, economists, and clinicians to collaborate on the development and application of longitudinal hierarchical discrete choice models for understanding diffusion of mental health technologies and for causal inference. Dr. Huskamp does not have any effort

budgeted for year two of this project. This project has a no-cost extension thru 7/31/09.

2008-2009	PI	Charles H. Farnsworth Trust	\$54,540
-----------	----	-----------------------------	----------

Hospice Utilization among Terminally Ill Nursing Home Residents in New England Communities

Using data from a large regional hospice serving nursing home residents in five New England states and data on nursing home characteristics and quality of care, we will document the variation in timing of hospice referral across nursing homes, identify patient characteristics and nursing home characteristics that are associated with earlier referral to hospice, and examine whether nursing homes that provide higher quality nursing care are more likely to make earlier referrals to hospice.

2008-2009	Co-Investigator	National Cancer Institute Grant #U01 CA093324	\$264,651
-----------	-----------------	--	-----------

Cancer Care Outcomes Research & Surveillance Consortium (CanCORS)	John Ayanian
---	--------------

The objectives of the CanCORS initiative are to: 1) enhance monitoring and understanding of the processes of cancer care and patient-centered factors influencing prognosis in population-based cohorts of lung and colorectal cancer patients; 2) establish a system for examining the relationship of the processes of care to clinical and patient-centered outcomes, with emphasis on measuring the dissemination of state-of-the science interventions and their association with better quality outcomes in the general population of cancer patients; and 3) examine disparities in the receipt of state-of-the-science cancer care and factors that contribute to disparities in outcomes and identify ways to lessen those disparities. This project is in a no cost extension phase.

2008-2011	PI	National Institute of Mental Health Grant #R01 MH080797	\$641,014
-----------	----	--	-----------

Effects of Mental Health Parity on High-Cost and Severely-Ill Individuals

Mental health parity policies aim to protect individuals with severe mental illnesses against the catastrophic costs of seeking treatment, and, in doing so, increase efficiency and fairness in the insurance market. In 2001, all plans participating in the Federal Employees Health Benefits (FEHB) Program were required to offer coverage for MH/SA services on a par with general medical services. This study will: 1) assess whether individuals with high MH/SA expenditures disproportionately benefited from the comprehensive FEHB parity policy, 2) compare characteristics of high spenders before and after parity adoption, and 3) examine how parity affected the composition, intensity, and quality of treatment received.

2009-2014	Co-Investigator	National Institute on Aging Grant #PO1 AG032952	\$6,593,439
-----------	-----------------	--	-------------

The Role of Private Plans in Medicare

The Program Project intends to undertake a fundamental examination of the economics of Medicare Part C, or Medicare Advantage (MA) from a framework grounded in economic theory. The Project is organized around five integrated component projects studying: 1) The factors influencing beneficiary choice of MA plan or traditional Medicare (TM); 2) How MA plans decide about entry and choose the overall generosity of benefits, depending upon Medicare payment policy; 3) Plans' choice of the mix or structure of their benefits in light of possible opportunities for efficiencies from integration and incentives for selection due to imperfect risk adjustment; (4) The consequences (spillovers) of plan choices about entry and practice patterns for beneficiaries in TM and non-Medicare populations; and 5) The design optimal payment, regulatory, and informational policies for Medicare to set for MA plans.

2009-2012	PI	National Institute on Aging Grant #R01 AG034085	\$247,190
-----------	----	--	-----------

Medicare Part D Plan Generosity & Dual-Eligible Nursing Home Residents

This study will examine the effect of Medicare Part D drug plan generosity on medication use and health outcomes for dual-eligible nursing home residents. We will combine drug utilization data from a large long term care pharmacy, data on health outcomes from the Minimum Data Set (MDS), and Medicare Part A hospitalization claims for the period 2005-2008.

2009-2010	Multiple PI	Medicare Payment Advisory Commission (MEDPAC)	\$43,682
-----------	-------------	--	----------

Medicare Part D, long-term care pharmacies (LTCs), and nursing facilities

To update previous work on the impact of Part D in the nursing home setting, we will conduct interviews of key stakeholders on the impact of Part D on medication access, care delivery, and quality of care outcomes for nursing home residents.

Current Unfunded Projects

2009-2011	Multiple PI	Data Infrastructure for Nursing Home Comparative Effectiveness & Use Studies	
-----------	-------------	--	--

This project will create a comprehensive data infrastructure to conduct future comparative effectiveness studies of therapies delivered in the nursing home setting.

2009-2013	Multiple PI	Drug Cost Containment Changes and Quality of Care for Mentally Ill	
-----------	-------------	--	--

Dual Enrollees

This study will examine the impact of the shift from Medicaid drug coverage to Medicare Part D among dual-eligibles with schizophrenia or bipolar disorder.

2010-2013 Multiple PI Assessing the effect of FDA advisories on psychotropic medications
This project will assess the impact of FDA safety advisories and black box warnings on prescription drug utilization by patients and physician prescribing patterns for three classes of psychotropic medications (antidepressants, antipsychotics, and stimulants).

Report of Local Teaching and Training

Teaching of Students in Courses:

1999-2005 Approximately 25 first-year medical students	HC704 Co-Director	1 two-hour session a week for 14 weeks
2007-2009 140 second-year medical students	HC750 Co-Director	1 two-hour session a week for 14 weeks
2010- 160 first-year medical students	HC750 Co-Director	5 two-hour sessions a week for 4 weeks

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs):

1997- 20-25 first-year doctoral students in Health Policy	Doctoral Seminar in Health Care Policy Harvard University Ph.D. Program in Health Policy	1-4 lectures per year
1997- 3-8 second-year doctoral students in Health Economics	Doctoral Seminar in Health Economics Harvard University Ph.D. Program in Health Policy	1-2 lectures per year
2000-2001 25-30 masters' students in Public Policy	Introduction to Health Care Policy John F. Kennedy School of Government	1 lecture per year
2004-2006 8-10 clerkship students	Introduction to the U.S. Health Care System Cambridge Hospital Integrated Clerkship Program	1 lecture per year

2005-2006 8 fellows	Introduction to Health Care Policy Beth Israel Deaconess Medical Center—Fellowship in Geriatric Medicine	3 lectures per year
------------------------	---	---------------------

2007 12-15 third-year medical students	Medicare, Medicaid and Rising U.S. Health Care Costs Harvard Medical School/Brigham and Women’s Hospital—Patient- Doctor III Tutorial	1 lecture
---	---	-----------

Formally Supervised Trainees:

Year(s)	Name and degrees	Current position
1997-2000 Dissertation Committee Member—Supervised completion of three dissertation essays and two papers in peer-reviewed journals	Susan Busch, Ph.D.	Associate Professor, Yale University
2000-2002 Dissertation Committee Member—Supervised completion of three dissertation essays	David Auerbach, Ph.D.	Health Economist, U.S. Congressional Budget Office
2001-2004 Dissertation Committee Member—Supervised completion of three dissertation essays and three papers in peer-reviewed journals	Colleen Barry, Ph.D.	Associate Professor, Yale University
2001-2002 Undergraduate Thesis Advisor for Harvard College—Supervised completion of senior thesis	Andrea Magyera	Current position unknown
2002-2004 Dissertation Committee Member—Supervised completion of three dissertation essays and one paper in peer-reviewed journal	Laura Eselius, Ph.D.	Manager, Deloitte Research
2003-2005 Dissertation Committee Member—Supervised completion of three dissertation essays and one paper in peer-reviewed journals	Stephanie Shimada, Ph.D.	Research Assistant Professor of Health Policy and Management, Boston University, Boston MA
2004-2007	Yuting Zhang, Ph.D.	Assistant Professor, University of Pittsburgh

Dissertation Committee Member—Supervised completion of three dissertation essays and three papers in peer-reviewed journals

2007-2009 Katy Backes Kozhimannil, M.P.A. Post-doctoral Fellow, Harvard Medical School, Department of Ambulatory Care and Prevention

Dissertation Committee Co-Chair—Supervised completion of three dissertation essays and two papers in peer-reviewed journals (thus far)

2008- Samuel Kina Current student
Dissertation Committee Member

2008- Jennifer Polinski Current student
Dissertation Committee Member

2008-2009 Kyle Gibler Student, Duke University School of Medicine

Undergraduate Thesis Advisor for Harvard College—Supervised completion of senior thesis

Report of Regional, National and International Invited Teaching and Presentations

1996 Managed Behavioral Health Care Carve-outs in Presented original research
Atlanta, GA the Private Sector Association for Health Services
Research Annual Meeting

1996 Risk Sharing Schemes in Managed Behavioral Presented original research
Bethesda, MD Health Care and the Incentives They Create National Institute of Mental
Health Biennial Research
Conference of the Economics of
Mental Health

1997 Empirical Clues about the Consequences of Presented original research
Chicago, IL Parity Legislation under Managed Care Association for Health Services
Research Annual Meeting

1998 Empirical Clues about the Consequences of Presented original research
Bethesda, MD Parity Legislation under Managed Care National Institute of Mental
Health Biennial Research
Conference of the Economics of
Mental Health

1998 Managed Care Incentives and Substance Abuse Presented original research
Washington, DC Treatment American Public Health
Association Annual Meeting

1999 Rotterdam, Netherlands	Financial Incentives and the Treatment of Depression	Presented original research International Health Economics Association Biennial Conference
1999 San Francisco, CA	A Partnership to Study Financial Incentives, Mental Health and Substance Abuse Treatment and Workplace Performance	Invited panelist Business for Social Responsibility Annual Conference
2000 Washington, DC	The Medicare Prescription Drug Benefit: How Will the Game Be Played?	Invited panelist National Health Policy Forum
2000 Atlanta, GA	Medicare Financing of End-of-Life Care: Issues Raised by Providers and Suggestions for Change	Presented original research American Academy of Hospice and Palliative Medicine Annual Assembly
2000 Worcester, MA	The Economics of Mental Health	Presented educational lecture Massachusetts State Area Medical Directors
2000 New York, NY	Providing Care at the End of Life: An Assessment of Medicare Coverage and Reimbursement	Invited presenter Project on Death in America Advisory Board Meeting
2000 New York, NY	Providing Care at the End of Life: An Assessment of Medicare Coverage and Reimbursement	Presented original research First International Geriatric Palliative Care Congress
2000 Denver, CO	Economics of Mental Health	Presented educational lecture Harvard University/National Association of State Mental Health Program Directors Executive Training Program
2001 New Orleans, LA	Moving Market Share: Drug Formularies and Demand Elasticity	Presented original research American Economics Association Annual Meeting
2001 York, England	Carve-outs and Cost Shifting	Presented original research International Health Economics Association Biennial Conference
2001 Arlington, VA	Reference Pricing	Presented original research International Society for

		Pharmacoeconomics and Outcomes Research Annual International Meeting
2001 Bethesda, MD	What is Known about the Economics of End-of-Life Care for Medicare Beneficiaries?	Presented original research National Institutes of Health Integrative Workshop on End-of-Life Research
2002 Bethesda, MD	Economics of Drug Formularies	Presented original research National Institute of Mental Health Pharmacoeconomics Research Workshop
2002 Cambridge, MA	Economics of Three-Tier Formularies	Invited presenter Harvard Medical School Conference on Health Economics in Managed Care
2002 Charlottesville, VA	Basics of Mental Health Economics	Invited presenter American Psychiatric Association Board of Trustees Retreat
2002 Denver, CO	Economics of Mental Health	Presented educational lecture Harvard University/National Association of State Mental Health Program Directors Executive Training Program
2003 Venice, Italy	The Impact of Three-tier Formularies on Prescription Drugs Used by Patients With Mental Illness	Presented original research International Center of Mental Health Policy and Economics Workshop on Costs and Assessment in Psychiatry
2003 Boston, MA	Economics of Three-tier Formularies	Invited presenter Boston University/Harvard University/Massachusetts Institute of Technology Joint Seminar on Health Economics
2003 Chicago, IL	Impact of Three-tier Formularies on Cost and Utilization Patterns	Invited presenter University of Chicago Harris School of Public Policy

2003 Chicago, IL	Impact of Incentive Formularies on Drug Utilization and Spending	Presented original research American Statistical Association International Conference on Health Policy Research
2003 Phoenix, AZ	Formulary Use in the Treatment of Depression	Invited presenter The Robert Wood Johnson Foundation's Annual Meeting of the Depression in Primary Care Program
2003 New York, NY	Future Research Directions in Pediatric Palliative Care: Financing and Economics	Presented original research New York Academy of Medicine, Initiative for Pediatric Palliative Care National Symposium
2003 Boston, MA	The Impact of Incentive Formularies	Invited presenter Harvard Medical School Conference on Health Economics in Managed Care
2004 New Haven, CT	The Impact of Three-Tier Formularies on Drug Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children	Invited presenter Yale University
2004 Waltham, MA	The Impact of Three-Tier Formularies on Drug Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) in Children	Invited presenter Brandeis University
2004 Washington, DC	The New Medicare Drug Benefit: Potential Effects of Pharmacy Management Tools on Access to Medications	Invited presenter Henry J. Kaiser Family Foundation
2004 Chicago, IL	The Impact of Three-Tier Formularies on Cost and Patient Compliance	Presented original research Institute for International Research Pharmacy Cost Management Conference
2004 Washington, DC	The Impact of Three-Tier Formularies on Drug Treatment of ADHD in Children	Presented original research National Institute of Mental Health Twelfth Biennial Research Conference on the Economics of Mental Health

2004 Philadelphia, PA	Formularies and Cost Sharing Issues for Medicare Part D	Invited presenter The Robert Wood Johnson Foundation's State Coverage Initiatives' Invitational Summit for State Policy Makers on Medicare Part D Implementation Issues
2005 Washington, DC	The Effect of Three-Tier Formulary on Medication Continuation and Spending Among Elderly Retirees	Invited presenter RAND Health
2005 Bethesda, MD	Medicare Modernization Act and Prescription Drug Pricing	Presented original research National Institute of Mental Health Third Pharmacoeconomics Workshop
2005 Cambridge, MA	The Impact of Parity Mental Health and Substance Abuse Benefits in the Federal Employees' Health Benefits Program	Invited presenter Mathematica Policy Research
2005 Boston, MA	The Effect of Three-Tier Formulary Adoption on Medication Continuation and Spending Among Elderly Retirees	Presented original research AcademyHealth Annual Research Meeting
2005 Boston, MA	Medicare Modernization Act: The Impact of State Implementation Decisions	Presented original research AcademyHealth Annual Research Meeting
2005 Boston, MA	The Impact of Federal Employees' Health Benefits Program Parity on Use and Cost of Mental Health and Substance Abuse Services	Presented original research AcademyHealth Annual Research Meeting
2006 Boston, MA	The Effect of Incentive Formularies on Medication Continuation and Spending among Elderly Retirees	Invited presenter Harvard Medical School, Department of Ambulatory Care and Prevention
2006 Boston, MA	Utilization Patterns and Costs for One Large Hospice: Lessons for Medicare per Diem Payment System?	Invited presenter Harvard University, Robert Wood Johnson Foundation Scholars Program
2006 Bethesda, MD	Manufacturer Promotional Strategies for SSRIs	Presented original research National Institute of Mental Health Biennial Conference on

		the Economics of Mental Health
2006 Boston, MA	Square Peg, Round Hole? Medicare Part D and Nursing Homes	Invited presenter Beth Israel Deaconess Medical Center, Gerontology Division Ground Rounds
2006 Boston, MA	The Impact of the Federal Employees' Health Benefits Program Mental Health Parity Policy on Use and Costs	Presented original research American Public Health Association Annual Meeting
2007 Washington, DC	Medicare Part D and Pharmacy Services to Residents of Nursing Homes," (joint with David Stevenson, Ph.D.)	Invited presenter Medicare Payment Advisory Commission
2007 San Diego, CA	Has the Revolution Come and Gone? The Societal Value of New Psychotropic Drugs	Presented original research The Robert Wood Johnson Foundation Investigator Awards in Health Policy Research Annual Meeting
2008 Boston, MA	Hospice Decision Making by Advanced Lung Cancer Patients	Invited presenter Dana Farber Cancer Outcomes Research Seminar
2008 Boston, MA	Hospice Care Delivery and Costs: Is There a Better Way?	Invited presenter Boston Bar Association
2008 Washington, DC	Who Uses New Product Formulations of Psychiatric Medications?	Presented original research AcademyHealth Annual Research Meeting
2008 Boston, MA	Discussions about Hospice among Patients with Advanced Lung Cancer	Invited presenter National Cancer Institute Cancer Consortium Meeting
2008 Durham, NC	Who Uses New Product Formulations of Psychiatric Medications?	Presented original research American Society for Health Economists
2008 Bethesda, MD	New Product Formulations of Antidepressants: What is the Social Value?	Presented original research National Institute of Mental Health Biennial Conference on the Economics of Mental Health
2008	New Product Formulations of Antidepressants:	Invited presenter

New Haven, CT	What is the Social Value?	Yale University School of Public Health
2009 Lausanne, Switzerland	Antidepressant Reformulations: Who Uses Them and What Are the Benefits?	Invited presenter University of Lausanne
2009 Chicago, IL	Discussions with Physicians about Hospice among Patients with Metastatic Lung Cancer	Presented original research AcademyHealth Annual Research Meeting

Report of Education of Patients and Service to the Community

1996	Advisor	State of Arizona, Office of the Auditor General
1996-1997	Member, Development Team for Technical Assistance Publication	U.S. Public Health Service, Substance Abuse and Mental Health Services Administration
1997-1998	Member, Technical Advisory Panel	The Robert Wood Johnson Foundation Home Care Research Initiative
1999-2000	Consultant, Veterans Administration Pharmacy Formulary Analysis Committee	Institute of Medicine
1999-2004	Co-Sponsor, Joint Seminar on Health Economics	Boston University, Harvard University, Massachusetts Institute of Technology
2000-2002	Member, Advocacy Committee	Coalition for Health Services Research
2001-2002	Member, Committee on Care for Children Who Die and Their Families	Institute of Medicine
2002-2009	Associate Member	MacArthur Foundation Network on Mental Health Policy
2002-2003	Chair, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2003-2005-2006	Member, Advisory Board, Policy Synthesis Project Member, Behavioral Health Committee	Robert Wood Johnson Foundation AcademyHealth Annual Research Meeting
2006-2007	Commission Member, Special Commission on Ambulatory Surgical Centers and Magnetic Resonance Imaging	Commonwealth of Massachusetts Senate and House of Representatives, Joint Committee on Health Care Financing
2006-2007	Member, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2008	Member, Expert Panel on Evaluating Plan Management of the Medicare Drug Benefit	Medicare Payment Advisory Commission (MedPAC)

2008-	Member, Consultation Team on Mental Health, Guide to Community Preventive Services	Centers for Disease Control and Prevention (CDC)
2008-2009	Chair, Behavioral Health Committee	AcademyHealth Annual Research Meeting
2009-	Member, Committee on Accelerating Rare Diseases Research and Orphan Products Development	Institute of Medicine
2009-	Member, Planning Committee	AcademyHealth Annual Research Meeting

Report of Scholarship

Publications:

1. **H.A. Huskamp** and J.P. Newhouse, "Is Health Spending Slowing Down?" *Health Affairs*, 13(5): 32-38, (1994).
2. R.G. Frank, **H.A. Huskamp**, T.G. McGuire and J.P. Newhouse, "Some Economics of Mental Health Carve-outs," *Archives of General Psychiatry*, 53: 933-937, (1996).
3. R.G. Frank and **H.A. Huskamp**, "Shaping National Policy: Delegation and Decentralization of Mental Health Care," *Current Opinion in Psychiatry*, 9: 171-174, (1996).
4. **H.A. Huskamp**, V. Azzone and R.G. Frank, "Carve-outs, Women, and the Treatment of Depression," *Women's Health Issues*, 8(5): 267-282, (1998).
5. **H.A. Huskamp**, "How A Managed Behavioral Health Care Carve-Out and Benefit Expansion Affected Spending on Treatment Episodes," *Psychiatric Services*, 49(11): 1559-1562, (1998).
6. M.B. Rosenthal, R.D. Geraty, R.G. Frank and **H.A. Huskamp**, "Psychiatric Provider Practice Management Companies: Adding Value to Behavioral Health Care?" *Psychiatric Services*, 50(8): 1011-1013, (1999).
7. **H.A. Huskamp** and J.P. Newhouse, "Future Directions for the National Health Accounts," *Health Care Financing Review*, 21(2): 5-13, (1999).
8. **H.A. Huskamp**, "Episodes of Mental Health and Substance Abuse Treatment under a Managed Behavioral Health Care Carve-out," *Inquiry*, 36(2): 147-161, (1999).
9. **H.A. Huskamp**, M.B. Rosenthal, R.G. Frank and J.P. Newhouse, "The Medicare Prescription Drug Benefit: How Will the Game Be Played," *Health Affairs*, 19(2): 8-23, (2000).
10. K.W. Hanson, **H.A. Huskamp**, D.W. Garnick and C. Horgan, "Mental Health and Substance Abuse Services under Medicaid Managed Care: The Uncertain Implications of State Variation," *Psychiatric Services*, 52(4): 447-456, (2001).
11. **H.A. Huskamp**, D.W. Garnick, K.W. Hanson and C. Horgan, "The Impact of Medicaid Managed Care Plan Withdrawals on Behavioral Health Services," *Psychiatric Services*, 52(5): 600-604, (2001).

12. **H.A. Huskamp**, M.B. Buntin, V. Wang and J.P. Newhouse, "Providing Care at the End of Life: Do Medicare Rules Impede Good Care?" *Health Affairs*, 20(3): 204-211, (2001).
13. M.B. Rosenthal, B.E. Landon and **H.A. Huskamp**, "Managed Care and the Role of Physician Organizations in Four Markets," *Health Affairs*, 20(5): 187-193, (2001).
14. B.E. Landon, **H.A. Huskamp**, C. Tobias and A.M. Epstein, "The Evolution of Quality Management by State Medicaid Agencies: A National Survey of States with Comprehensive Managed Care Programs," *Joint Commission Journal on Quality Improvement*, 28(2): 72-82, (2002).
15. The Harvard Managed Care Industry Center Group (H. Bailit, D. Blumenthal, J. Buchanan, M. Beeuwkes Buntin, D. Caudry, P. Cleary, A. Epstein, P. Fitzgerald, R. Frank, H. Gorski, **H. Huskamp**, N. Keating, B. Landon, B. McNeil, J. Newhouse, M. Rosenthal, A. Zaslavsky). "Managed Care: An Industry Snapshot," *Inquiry* 39(3): 207-220, (2002).
16. M.B. Buntin and **H.A. Huskamp**, "What is Known About the Economics of End-of-Life Care for Medicare Beneficiaries?" *The Gerontologist*, Vol. 42, Special Issue III, (2002).
17. **H.A. Huskamp**, A.M. Epstein and D. Blumenthal, "The Impact of a National Prescription Drug Formulary on Prices, Market Share, and Spending: Lessons for Medicare?" *Health Affairs*, 22(3): 149-158, (2003).
18. R.G. Frank, **H.A. Huskamp** and H.A. Pincus, "Aligning Incentives in the Treatment of Depression in Primary Care," *Psychiatric Services*, 54(5): 682-687, (2003).
19. **H.A. Huskamp**, "Managing Psychotropic Drug Costs: Will Formularies Work?" *Health Affairs*, 22(5): 84-96, (2003).
20. **H.A. Huskamp**, P.A. Deverka, A.M. Epstein, R.S. Epstein, K.A. McGuigan and R.G. Frank, "The Impact of Incentive Formularies on Prescription Drug Utilization and Spending," *New England Journal of Medicine*, 349(23): 2224-2232, (2003).
21. S.F. Greenfield, V. Azzone, **H.A. Huskamp**, B. Cuffel, T. Croghan, W. Goldman, and R.G. Frank, "Treatment for Substance Use Disorders in a Privately Insured Population under Managed Care: Costs and Services Use," *Journal of Substance Abuse Treatment*, 27(4): 265-275, (2004).
22. **H.A. Huskamp**, P.A. Deverka, A.M. Epstein, R.S. Epstein, K.A. McGuigan, A.C. Muriel, and R.G. Frank, "The Impact of Three-Tier Formularies on Treatment of Attention-Deficit/Hyperactivity Disorder in Children," *Archives of General Psychiatry* 62(4): 435-441, (2005) .
23. **H.A. Huskamp** and N.L. Keating, "The New Medicare Drug Benefit: Formularies and Their Potential Effects on Access to Medications," *Journal of General Internal Medicine* 20(7):662-665, (2005).
24. M.E. Domino and **H.A. Huskamp**, "Does Provider Variation Matter to Health Plans?" *Journal of Health Economics* 24(4): 795-813, (2005).

25. **H.A. Huskamp**, R.G. Frank, K.A. McGuigan and Y. Zhang, "The Impact of a Three-Tier Formulary on Demand Response for Prescription Drugs," *Journal of Economics and Management Strategy* 14(3): 729-753, (2005).
26. **H.A. Huskamp**, "Pharmaceutical Cost Management and Access to Psychotropic Drugs: The U.S. Context," *International Journal of Law and Psychiatry* 28(5):484-495, (2005).
27. **H.A. Huskamp** and J.A. Shinogle, "The New Medicare Drug Benefit: Effects on Pricing for Psychotropic Medications?" *Psychiatric Services* 56(9):1056-1058, (2005).
28. N.L. Keating, M. Norredam, M.B. Landrum, **H.A. Huskamp**, and E.R. Meara, "Physical and Mental Health Status of Older Long-Term Cancer Survivors," *Journal of the American Geriatrics Society* 53:2145-2152, (2005).
29. W.F. Gellad, **H.A. Huskamp**, K.A. Phillips, and J.S. Haas, "Assessing the Impact of the Standard Medicare Drug Benefit on Out-of-Pocket Drug Costs for Vulnerable Populations," *Health Affairs* 25(1): 248-245, (2006).
30. H.H. Goldman, R.G. Frank, M.A. Burnam, **H.A. Huskamp**, et al., "Evaluating the Impact of Parity Mental Health and Substance Abuse Benefits in the Federal Employees' Health Benefits Program," *New England Journal of Medicine* 354(13):1378-1386, (2006).
31. A.B. Busch, **H.A. Huskamp**, S.T. Normand, A.S. Young, H. Goldman, and R.G. Frank, "The Impact of Parity on Major Depression Treatment Quality in the Federal Employees' Health Benefits Program After Parity Implementation," *Medical Care* 44(6): 506-512, (2006).
32. **H.A. Huskamp**, "Prices, Profits and Innovation: Examining Criticisms of the Value of New Psychotropic Drugs," *Health Affairs* 25(3):635-646, (2006).
33. D.C. Grabowski, D.G. Stevenson, **H.A. Huskamp**, and N.L. Keating, "The Influence of Medicare Home Health Payment Incentives: Does Payer Source Matter?" *Inquiry* 43(2):135-149, (2006).
34. **H.A. Huskamp**, A.D. Sinaiko, and J.P. Newhouse, "Future Directions for the National Health Expenditure Accounts: Conference Overview," *Health Care Financing Review* 28(1):1-8, (2006).
35. S.T. Azrin, **H.A. Huskamp**, V. Azzone, H.H. Goldman, et al., "Impact of Full Mental Health and Substance Abuse Parity for Children in the Federal Employees Health Benefits Program," *Pediatrics* 119: 452-459, (2007). Available at www.pediatrics.org.
36. **H.A. Huskamp**, D.G. Stevenson, J.M. Donohue, J.P. Newhouse, and N.L. Keating, "Coverage and Prior Authorization of Psychotropic Drugs under Medicare Part D," *Psychiatric Services* 58(3):308-310, (2007).
37. **H.A. Huskamp**, P.A. Deverka, M.B. Landrum, R.S. Epstein and K.A. McGuigan, "The Effect of Three-Tier Formulary Adoption on Medication Continuation and Spending Among Elderly Retirees," *Health Services Research* 42(5):1926-1942, (2007).

38. D.G. Stevenson, **H.A. Huskamp**, N.L. Keating, and J.P. Newhouse, "Medicare Part D and Nursing Home Residents," *Journal of the American Geriatrics Society* 55(7): 1115-1124, (2007).
39. A.B. Busch, M.B. Landrum and **H.A. Huskamp**, "Quality of Care for Bipolar-I Disorder in a Medicaid Population: Does Presenting Diagnosis or Locus of Care Matter?" *Psychiatric Services* 58(6):848-854, (2007).
40. M.B. Rosenthal, M.B. Landrum, **H.A. Huskamp**, E. Meara, R.M. Conti, and N.L. Keating, "Using Performance Data to Identify Preferred Hospitals," *Health Services Research* 42(6):2109-2119, (2007).
41. W.F. Gellad, **H.A. Huskamp**, K.A. Phillips, and J.S. Haas, "Angiotensin Receptor Blockers on the Formularies of Medicare Drug Plans," *Journal of General Internal Medicine* 22(8):1172-1175, (2007).
42. D.G. Stevenson, **H.A. Huskamp**, D.C. Grabowski, and N.L. Keating, "Differences in Hospice Care between Home and Institutional Settings," *Journal of Palliative Medicine* 10(5):1040-1047 (2007).
43. M.O. Edelen, M.A. Burnam, K. Watkins, J. Escarce, H. Goldman, **H. Huskamp**, and G. Rachelevsky, "Obtaining Utility Estimates of the Health Value of Commonly-Prescribed Treatments for Asthma and Depression," *Medical Decision Making* 28: 732-750, (2008).
44. D.G. Stevenson, **H.A. Huskamp**, and J.P. Newhouse, "Medicare Part D and the Nursing Home Setting," *The Gerontologist* 48(4):432-441, (2008).
45. **H.A. Huskamp**, J.P. Newhouse, J.C. Norcini, and N.L. Keating, "Variation in Patients' Hospice Costs," *Inquiry* 45(2): 232-244, (2008).
46. **H.A. Huskamp**, D.G. Stevenson, N.L. Keating, and J.P. Newhouse, "Rejections of Drug Claims for Nursing Home Residents under Medicare Care Part D," *Health Affairs* 27(2): 560-567, (2008).
47. **H.A. Huskamp**, J.M. Donohue, C. Koss, E.R. Berndt, and R.G. Frank, "Generic Entry, Reformulations and Promotion of SSRIs in the U.S.," *Pharmacoeconomics* 26(7):603-616, (2008).
48. J.M. Donohue, M. Fischer, **H.A. Huskamp**, and J. Weissman, "Potential Savings from an Evidence-Based, Consumer-Oriented Public Education Campaign on Prescription Drugs," *Health Services Research* 43(5):1557-1575, (2008).
49. L.L. Eselius, P.D. Clearly, A.M. Zaslavsky, **H.A. Huskamp**, and S.H. Busch, "Case-Mix Adjustment of Consumer Reports about Managed Behavioral Health Care and Health Plans," *Health Services Research* 43(6):2014-2032, (2008).
50. D.C. Grabowski, **H.A. Huskamp**, D.G. Stevenson, and N.L. Keating, "Ownership Status and Home Health Care Performance," *Journal of Aging & Social Policy* 21(2):130-143, (2009).
51. B. Zhang, A.A. Wright, **H.A. Huskamp**, M.E. Nilsson, M.L. Maciejewski, C.C. Earle, S.D. Block, P.K. Maciejewski, and H.G. Prigerson, "Health Care Costs in the Last Week of Life: Associations with End-of-Life Conversations," *Archives of Internal Medicine* 169(5):480-488, (2009).

52. **H.A. Huskamp**, A.B. Busch, M.E. Domino, and S-L Normand, “Antidepressants Reformulations: Assessing the Benefits” *Health Affairs* 28(3):734-745, (2009).
53. J.M. Donohue, **H.A. Huskamp**, and S.H. Zuvekas, “Dual-eligibles with Mental Disorders and Part D: How Are They Faring?” *Health Affairs* 28(3):746-759, (2009).
54. K.E. Watkins, M.A. Burnam, M. Orlando, J. Escarce, **H.A. Huskamp**, and H.H. Goldman, “The Health Value and Cost of Care for Major Depression,” forthcoming in *Value in Health*.
55. J.M. Donohue, **H.A. Huskamp**, I.B. Wilson, and J. Weissman, “Consumer Communications with Doctors and Pharmacists about Prescription Drug Costs,” *American Journal of Geriatric Pharmacotherapy* 7(2):105-116, (2009).
56. **H.A. Huskamp**, N.L. Keating, J.L. Malin, A.M. Zaslavsky, J.C. Weeks, C.C. Earle, J.M. Teno, B.A. Virnig, K.L. Kahn, Y. He, and J.Z. Ayanian, “Discussions with Physicians about Hospice among Patients with Metastatic Lung Cancer,” *Archives of Internal Medicine* 169(10):954-962, (2009).
57. **H.A. Huskamp**, J.C. West, D.S. Rae, M. Rubio-Stipec, D.A. Regier, and R.G. Frank, “Part D and Dual Eligibles with Mental Illness: Problems Accessing Medications and Implications for Use of Intensive Mental Health Services,” *Psychiatric Services* 60(9):1169-1174, (2009).
58. **H.A. Huskamp** and M.B. Rosenthal, “Health Risk Appraisals in Employer-Sponsored Insurance: A Meaningful Way to Engage Consumers?” *Health Affairs* 28(5):1532-1540, (2009).
59. C.L. Barry, H.H. Goldman, R.G. Frank, and **H.A. Huskamp**, “Lessons for Health Reform from the Hard-won Success of Behavioral Health Insurance Parity,” *American Journal of Psychiatry* 166(9):969-971, (2009).
60. A.B. Busch, **H.A. Huskamp**, B. Neelon, T. Manning, S.T. Normand, and T.G. McGuire, “Longitudinal Racial/Ethnic Disparities in Antimanic Medication Prescribing for Bipolar-I Disorder,” forthcoming in *Medical Care*.
61. M. Norredam, E. Meara, M.B. Landrum, **H.A. Huskamp**, and N.L. Keating, “Financial Status, Employment and Insurance among Older Cancer Survivors,” forthcoming in *Journal of General Internal Medicine*.
62. N.L. Keating, M.B. Landrum, S.O. Rogers, S.K. Baum, B.A. Virnig, **H.A. Huskamp**, C. C. Earle, and K.L. Kahn, “Physician Factors Associated with Discussions about End-of-Life Care,” forthcoming in *Cancer*.

Original Articles under Review

1. D.G. Stevenson, S.L. Decker, L.L. Dwyer, **H.A. Huskamp**, D.C. Grabowski, E.D. Metzger, and S.L. Mitchell, “Antipsychotic and Benzodiazepine Use among Nursing Home Residents”

2. K. Backes Kozhimannil, **H.A. Huskamp**, A.B. Busch, S.B. Soumerai, and A.S. Adams, “Impact of a Statewide Postpartum Depression Initiative on Mental Health Care after Delivery among Low-Income Women”
3. **H.A. Huskamp**, D.G. Stevenson, M.E. Chernew, and J.P. Newhouse, “The Medicare Hospice Benefit: A Good Fit for Nursing Home Residents?”
4. J. Zhu, P. Zawarsky, S. Lipsitz, **H.A. Huskamp**, and J.S. Haas, “Massachusetts Health Reform and Disparities in Coverage, Access, and Health Status”

Reviews, Chapters, and Editorials

1. **H.A. Huskamp**, “Managed Behavioral Health Care Carve-out RFPs and Contracts for Individuals with Severe Mental Illness,” monograph prepared for the National Alliance for the Mentally Ill, (1996).
2. R. Conti, E. Dorosh, A.M. Epstein, R.G. Frank, **H.A. Huskamp** and M.B. Rosenthal, “Drug Policy Issues in California,” monograph prepared for the California Health Care Foundation, (1999).
3. **H.A. Huskamp**, Comment on Sensenig A. and Wilcox E. “National Health Accounts/National Income and Product Accounts Reconciliation,” Chapter 7 in *Medical Care Output and Productivity*, edited by David M. Cutler and Ernst R. Berndt, National Bureau of Economic Research, Studies in Income and Wealth, Volume 62, pp. 300-302 (2001).
4. **H.A. Huskamp** and N.L. Keating, “The New Medicare Drug Benefit: Potential Effects of Pharmacy Management Tools on Access to Medications,” Henry J. Kaiser Foundation, July 2004.
5. D.G. Stevenson, **H.A. Huskamp**, and Joseph P. Newhouse, “Medicare Part D, Nursing Homes, and Long-Term Care Pharmacies,” report to the Medicare Payment Advisory Commission, March 2007.

Narrative Report

Dr. Huskamp has three primary areas of research: 1) mental health policy; 2) prescription drug policy; and 3) the financing and utilization of end-of-life care services.

Dr. Huskamp has developed a body of research on the impact of pharmacy management tools used to control drug costs on drug utilization, cost, and quality of care. She has written numerous papers on the Medicare Part D drug benefit and its implications for vulnerable populations, including individuals with a mental illness and nursing home residents. She recently completed a Career Development Award from the National Institute of Mental Health focused on the economics of psychotropic medications. Through this award, she examined the impact of three-tier prescription drug formularies on cost and utilization patterns for drugs used to treat mental illness; the effect of generic entry of antidepressant medications on drug sales, market share, and advertising and promotional strategies of antidepressant manufacturers; and the implications of the Medicare Part D drug benefit for access to psychotropic medications, psychotropic drug pricing, and incentives for future

psychotropic innovation. Through a Robert Wood Johnson Foundation Investigator Award in Health Policy Research, Dr. Huskamp is currently comparing the social costs and benefits of newer psychotropic drugs to assess their social value and identify ways that the value of psychotropic drug spending can be increased. She currently serves as a member of the Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Products Development.

Dr. Huskamp has assessed the effect of implementing comprehensive mental health parity (i.e., requiring plans to offer the same level of coverage for mental health and general medical services) in the Federal Employees Health Benefits Program on use of mental health services, total and out-of-pocket mental health costs, and the likelihood of receiving appropriate treatment. She currently serves as Principal Investigator for an R01 funded by the National Institute of Mental Health on the effect of mental health parity on individuals with severe mental illnesses and high mental health service costs. Dr. Huskamp has published numerous papers on the impact of managed care for mental health services on utilization patterns, costs and quality of care.

Dr. Huskamp is currently completing a study of factors associated with discussing hospice care with a physician among metastatic lung cancer patients through funding provided by the National Cancer Institute and the Department of Veterans Affairs. Other recent work on end-of-life care includes a study of patient-level variation in hospice costs funded by the Agency for Healthcare Research and Quality and the Alfred P. Sloan Foundation, and a study of patient and nursing home factors that contribute to earlier referrals to hospice among terminally-ill nursing home residents funded by the Charles H. Farnsworth Trust. Dr. Huskamp previously served as principal investigator for a study funded by the Robert Wood Johnson Foundation to examine the impact of Medicare financing methods on the provision of services to patients at the end of life. She also served as a member of the Institute of Medicine Committee on Care for Children Who Die and Their Families.